Giant-Cell Tumor Treatment: Curettage Without Denosumab Is Better
Denosumab is an FDA-approved drug for osteoporosis. It works by binding RANKL, thus inhibiting osteoclastic activity. Denosumab  has also been …
What’s New in Orthopaedic Oncology
Every month, JBJS publishes a Specialty Update—a review of the most pertinent and impactful studies published in the orthopaedic literature …